For research use only. We do not sell to patients.

Voglibose

CAS No. : 83480-29-9

Biological Activity：Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.
Target: α-glucosidases
glibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].

Research Area：Metabolic Disease

Targets：Glucosidase

Related Screening Libraries:Natural Product Library Plus;Drug Repurposing Compound Library Plus;FDA-Approved Drug Library Plus;FDA-Approved Drug Library Mini;Bioactive Compound Library Plus;Metabolism/Protease Compound Library;Natural Product Library;FDA-Approved Drug Library;Drug Repurposing Compound Library;Anti-diabetic Compound Library;Ferroptosis Compound Library;Anti-COVID-19 Compound Library;NMPA-Approved Drug Library;FDA Approved & Pharmacopeial Drug Library;Drug-Induced Liver Injury (DILI) Compound Library;Microbial Metabolite Library;Anti-Obesity Compound Library;Glucose Metabolism Compound Library;Targeted Diversity Library;Human Metabolite Library;

Related Small Molecules:α-Glucosidase-IN-20;Ganoderic acid Y;Glucocerebrosidase-IN-1;α-Glucosidase-IN-21;α-Glucosidase-IN-17;Bisabolone oxide A;α-Glucosidase-IN-10;Glycosidase-IN-1;α-Glucosidase-IN-15;α-Glucosidase-IN-3;p-Hydroxyphenethyl trans-ferulate;HPA-IN-1;Norathyriol;Ganoderol B;α-Amylase/α-Glucosidase-IN-1;3β-Acetoxy-hop-22(29)-ene;Diphlorethohydroxycarmalol;α-Glucosidase-IN-8;(+)-Afzelechin;Celgosivir;Licochalcone C;Malabaricone B;HPA-IN-2;Rebaudioside A;α-Amylase/α-Glucosidase-IN-2;N-Nonyldeoxynojirimycin;α-Glucosidase-IN-2

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

About Us:

• MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use；
• Structurally and synthetically diverse biologically active compounds；
•  roduct quality is the key to our success and we take pride in offering only the highest-grade products.；
• We provide HNMR, LC-MS, HPLC, stability testing and activity assays of our products to clients.；
• Product identity, quality, purity and activity are assured by our robust quality control programs and procedures.；

Structurally and synthetically diverse biologically active compounds；

• Customized order volume ranging from milligrams to kilograms scale；

We provide customer-oriented services. To explore more, please contact us at [email protected]. Our team will gladly assist you.